nifedipine has been researched along with Albright Hereditary Osteodystrophy in 1 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this case, the unresponsiveness of the urinary phosphate secretion to cAMP was recovered by a high dose of cAMP or long-term administration of a phosphodiesterase inhibitor." | 1.30 | Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor. ( Fujiwara, K; Hayashi, R; Itoh, M; Kakizawa, H; Kobahashi, T; Makino, M; Mano, T; Nagasaka, A; Nagata, M; Nakai, A; Uchimura, K; Wada, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mano, T | 1 |
| Uchimura, K | 1 |
| Hayashi, R | 1 |
| Kobahashi, T | 1 |
| Fujiwara, K | 1 |
| Makino, M | 1 |
| Kakizawa, H | 1 |
| Nagata, M | 1 |
| Nakai, A | 1 |
| Wada, M | 1 |
| Nagasaka, A | 1 |
| Itoh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism[NCT03029429] | Phase 2 | 34 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism[NCT04551170] | Phase 2 | 34 participants (Anticipated) | Interventional | 2020-07-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for nifedipine and Albright Hereditary Osteodystrophy
| Article | Year |
|---|---|
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Topics: Bucladesine; Calcium; Calcium Channel Blockers; Calcium Compounds; Cyclic AMP; Female; Humans; Lacta | 1999 |
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Topics: Bucladesine; Calcium; Calcium Channel Blockers; Calcium Compounds; Cyclic AMP; Female; Humans; Lacta | 1999 |
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Topics: Bucladesine; Calcium; Calcium Channel Blockers; Calcium Compounds; Cyclic AMP; Female; Humans; Lacta | 1999 |
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Topics: Bucladesine; Calcium; Calcium Channel Blockers; Calcium Compounds; Cyclic AMP; Female; Humans; Lacta | 1999 |